- Home
- IMUX vs HSPO Comparison
IMUX vs HSPO Comparison
Compare IMUX & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- HSPO
- Stock Information
- Founded
- IMUX 2016
- HSPO 2014
- Country
- IMUX United States
- HSPO United States
- Employees
- IMUX N/A
- HSPO N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- HSPO Blank Checks
- Sector
- IMUX Health Care
- HSPO Finance
- Exchange
- IMUX Nasdaq
- HSPO Nasdaq
- Market Cap
- IMUX 102.2M
- HSPO 92.0M
- IPO Year
- IMUX N/A
- HSPO 2022
- Fundamental
- Price
- IMUX $1.09
- HSPO $11.89
- Analyst Decision
- IMUX Strong Buy
- HSPO
- Analyst Count
- IMUX 7
- HSPO 0
- Target Price
- IMUX $12.67
- HSPO N/A
- AVG Volume (30 Days)
- IMUX 555.7K
- HSPO 3.2K
- Earning Date
- IMUX 05-07-2025
- HSPO 01-01-0001
- Dividend Yield
- IMUX N/A
- HSPO N/A
- EPS Growth
- IMUX N/A
- HSPO 2.63
- EPS
- IMUX N/A
- HSPO 0.91
- Revenue
- IMUX N/A
- HSPO N/A
- Revenue This Year
- IMUX N/A
- HSPO N/A
- Revenue Next Year
- IMUX N/A
- HSPO N/A
- P/E Ratio
- IMUX N/A
- HSPO $12.82
- Revenue Growth
- IMUX N/A
- HSPO N/A
- 52 Week Low
- IMUX $0.92
- HSPO $10.87
- 52 Week High
- IMUX $2.11
- HSPO $12.41
- Technical
- Relative Strength Index (RSI)
- IMUX 46.81
- HSPO 69.57
- Support Level
- IMUX $1.18
- HSPO $11.61
- Resistance Level
- IMUX $1.28
- HSPO $11.75
- Average True Range (ATR)
- IMUX 0.07
- HSPO 0.01
- MACD
- IMUX -0.00
- HSPO 0.01
- Stochastic Oscillator
- IMUX 6.00
- HSPO 100.00
Stock Price Comparison Chart: IMUX vs HSPO
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.